The role of matrix metalloproteinases (MMPs) and their inhibitors in venous leg ulcer healing

Phlebolymphology

Volumn , Issue 44, 2004, Pages 231-243

  Herouy, Yared ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Chronic venous insufficiency; Lipodermatosclerosis; Metalloproteinase; Proteinases; Varicose veins; Venous leg ulcers

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

CHRONIC VEIN INSUFFICIENCY; DERMIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; EPIDERMIS; EXTRACELLULAR MATRIX; GENE IDENTIFICATION; HUMAN; HYDROLYSIS; LEG ULCER; LIPODERMATOSCLEROSIS; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SKIN DEFECT; ULCER; ULCER HEALING; WOUND;

EID: 1942423221     PISSN: 12860107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
2. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516.
3. Woessner JF. The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego, Calif: Academic Press; 1998:1-13.
4. Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111-122.
5. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267-283.
6. Herrick SE, Sloan P, McGurk M, et al. Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am J Pathol. 1992;141:1085-1095.
7. Browse NL, Burnand KG. The cause of venous ulceration. Lancet. 1982;2:243-245.
8. Coleridge Smith PD, Thomas P, Acurr JH et al. Causes of venous ulceration: A new hypothesis. BMJ. 1988;296:1726-1727.
9. Neumann HA, Van den Broek MJ. Increased collagen IV layer in the basal membrane area of the capillaries in severe chronic venous insufficiency. Vasa. 1991;20:26-29.
10. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol. 1999;11:614-621.
11. Raghow R. The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J. 1994;8:823-831.
12. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 1998;10: 602-608.
13. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol. 1995;7:728-735.
14. Powell WC, Matrisan LM. Complex roles of matrix metalloproteinases in tumor progression. Attempts to understand metastasis formation. In: Gunther U, Schlag PM, Birchmeier W, eds. Metastasis Related Molecules. Heidelberg, Germany: Springer-Verlag; 1996:1-21.
15. Seltzer JL, Jeffrey JJ, Eisen AZ. Evidence for mammalian collagenase as zinc ion metalloenzymes. Biochim Biophys Acta. 1977;485:179-187.
16. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol. 1996;156:1-4.
17. Saarialho-Kere UK, Pentland AP, Birkedal-Hansen H, et al. Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. J Clin Invest. 1994;94:79-88.
18. Lepage T, Gache C. Early expression of a collagenase-like hatching enzyme gene in the sea urchin embryo. EMBO J. 1990;9:3003-3012.
19. Leontovich AA, Zhang J, Shimokawa K, et al. A novel hydra matrix metalloproteinase (HMMP) functions in extracellular matrix degradation, morphogenesis and the maintenance of differentiated cells in the foot process. Development. 2000;127:907-920.
20. Maidment JM, Moore D, Murphy GP, et al. Matrix metalloproteinase homologues from Arabidopsis thaliana: expression and activity. J Biol Chem. 1999;274:34706-34710.
21. Allan JA, Docherty AJ, Barker PJ, et al. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J. 1995;309:299-306.
22. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase: inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the length fragments. J Biol Chem. 1995;270:5872-5876.
23. Patterson ML, Atkinson SJ, Knäuper V, et al. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett. 2001;503:158-162.
24. Itoh T, Ikeda T, Gomi H, et al. Unaltered secretion of β-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem. 1997;272: 22389-22392.
25. Martignetti JA, Aqeel AA, Sewairi WA, et al. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet. 2001;28:261-265.
26. Suzuki K, Enghild JJ, Morodomi T, et al. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry. 1990;29:10261-10270.
27. Uria JA, López-Otín C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res. 2000;60:4745-4751.
28. Park HI, Ni J, Gerkema FE, et al. Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem. 2000;275:20540-20544.
29. Ohuchi E, Imai K, Fujii Y, et al. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem. 1997;272:2446-2451.
30. Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-defident mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell. 1999;99:81-92.
31. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost. 2001;86:346-355.
32. Sekine-Aizawa Y, Hama E, Watanabe K, et al. Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain-specific MMP highly expressed in cerebellum. Eur J Neurosci. 2001;13:935-948.
33. Velasco G, Cal S, Merlos-Suárez A, et al. Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res. 2000;60:877-882.
34. Pei D. Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage. Cell Res. 1999;9:291-303.
35. Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem. 1993;268:23824-23829.
36. Shipley JM, Wesselschmidt RL, Kobayashi DK, et al. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA. 1996;93:3942-3946.
37. Péndas AM, Knäuper V, Puente XS, et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem. 1997;272:4281-4286.
38. Kolb C, Mauch S, Peter HH, et al. The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient. Immunol Lett. 1997;57:83-88.
39. Yang M, Kurkinen M. Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts: CMMP, Xenopus XMMP, and human MMP19 have a conserved unique cysteine in the catalytic domain. J Biol Chem. 1998;273:7893-17900.
40. Velasco G, Pendas AM, Fueyo A, et al. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem. 1999;274:4570-4576.
41. Marchenko GN, Strongin AY. MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. Gene. 2001;265:87-93.
42. Lohi J, Wilson CL, Roby JD, et al. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem. 2001;276:10134-10144.
43. Saarialho-Kere U, Kerkela E, Jahkola T, et al. Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. J Invest Dermatol. 2002;119:14-21.
44. Esteve PO, Tremblay P, Houde M, et al. In vitro expression of MMP-2 and MMP-9 in glioma cells following exposure to inflammatory mediators. Biochim Biophys Acta. 1998;1403:85-96.
45. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378: 151-160
46. Vaalomo M, Mattila L, Johansson N, et al. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dermatol. 1997;109:96-101.
47. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol. 1998;466-471.
48. Okada Y, Harris ED, Jr, Nagase H. The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts: purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem J. 1988;254:731-741.
49. Nagase H, Enghild JJ, Suzuki K, et al. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry. 1990;29:5783-5789.
50. Mazzieri R, Masiero L, Zanetta L, et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J. 1997;16:2319-2332.
51. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost. 2001;86:324-333.
52. Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72 kDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase. J Biol Chem. 1995;270:5331-5338.
53. Cao J, Sato H, Takino T, Seiki M. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for progelatinase A activation. J Biol Chem. 1995;270:801-805.
54. Murphy G, Stanton H, Cowell S, et al. Mechanisms for pro matrix metalloproteinase activation. APMIS. 1999;107:38-44.
55. Butler GS, Will H, Atkinson SJ, et al. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur J Biochem. 1997;244:653-657.
56. Takino T, Sato H, Shinagawa A, et al. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library: MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem. 1995;270:23013-23020.
57. Llano E, Pendas AM, Freije JP, et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A overexpressed in brain tumors. Cancer Res. 1999;59:2570-2576.
58. Pei D. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem. 1999;274:8925-8932.
59. English WR, Puente XS, Freije JM, et al. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor convertase activity but does not activate proMMP2. J Biol Chem. 2000;275:14046-14055.
60. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A: a kinetic study. J Biol Chem. 1998;273:871-880.
61. Wang Z, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem. 2000; 275:26411-26415.
62. Ward RV, Hembry RM, Reynolds JJ, et al. The purification of tissue inhibitor of metalloproteinase-2 form ist 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinase-2 and tissue inhibitor of metalloproteinse-1. Biochem J. 1991;278:179-187.
63. Wilde CG, Hawkins PR, Coleman RT, et al. Cloning and characterization of human tissue inhibitor of metalloproteinases-3. DNA Cell Biol. 1994;13:711-718.
64. Leco KJ, Apte SS, Taniguchi GT, et al. Murine tissue inhibitor of metalloproteinases-4 (TIMP-4) cDNA isolation and expression in adult mouse tissues. FEBS Lett. 1997;401:213-217.
65. Vaalamo M, Leivo T, Saarialho-Kere U. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2,-3 and -4) in normal and aberrant wound healing. Hum Pathol. 1999;30:795-802.
66. Howard EW, Bullen EC, Banda MJ. Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitors of metalloproteinase-2. J Biol Chem. 1991;266:13070-13075.
67. Williamson RA, Martorell G, Carr MD, et al. Solution structure of the active domain of tissue inhibitor of metalloproteinases-2: a new member of the OB fold protein family. Biochemistry. 1994;33:11745-11759.
68. Murphy G, Houbrechts A, Cockett MI, et al. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry. 1991;30:8097-8102
69. Will H, Atkinson SJ, Butler GS, et al. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation: regulation by TIMP-2 and TIMP-3. J Biol Chem. 1996;271:17119-17123.
70. Amour A, Slocombe PM, Webster A, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998;435: 39-44.
71. Amour A, Knight CG, Webster A, et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 2000;473:275-279.
72. Loechel F, Fox JW, Murphy G, et al. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun. 2000;278:511-515.
73. Kashiwagi M, Tortorella M, Nagase H, et al. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem. 2001;276:12501-12504.
74. Yu WH, Yu S, Meng Q, et al. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem. 2000;275:31226-31232.
75. Fedak PW, Altamentova SM, Weisel RD, et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol. 2003;284: H626-H634.
76. Vowden K. Lipodermatosderosis and atrophie blanche. J Wound Care. 1998;7: 441-443.
77. Herouy Y, Schöpf E, Vanscheidt W. Lipodermatosclerosis. Phleb Digest. 1998;3:6-8.
78. Weckroth M, Vaheri A, Lauharanta J, et al. Matrix metalloproteinases, gelatinase and collagenase in chronic leg ulcers. J Invest Dermatol 1996;106:1119-1124.
79. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol. 1993;101:64-68.
80. Herouy Y, May AE, Pornschlegel G, et al. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases. Implications for venous ulcer formation. J Invest Dermatol. 1998;111:822-827.
81. Jarret PE, Burnand KG, Morland M, et al. Proceedings: Fibrinolysis and fat necrosis in the lower leg. Br J Surg. 1976;63:157-160.
82. Herouy Y, Nockowski P, Schöpf E, et al. Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration. Int J Mol Med. 1999;3: 511-515.
83. Pilcher BK, Dumin JA, Sudbeck BD, et al. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. Cell Biol. 1997;137:1445-1457.
84. Sudbeck BS, Parks WC, Welgus HG, et al. Collagen-stimulated induction of keratinocyte collagenase is mediated via tyrosine kinase and protein kinase C activities. J Biol Chem. 1994;269:30022-30029.
85. Sudbeck BD, Pilcher BK, Pentland AP, et al. Modulation of intracellular calcium levels inhibits secretion of collagenase-1 by migrating keratinocytes. Mol Biol Cell. 1997;8:811-824.
86. Norgauer J, Hildenbrand T, Idzko M, et al. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol. 2002;147:1180-1186.
87. Herrick S, Ashcroft G, Ireland G, et al. Upregulation of elastase in acute wounds of healthy aged humans and chronic venous leg ulcers are associated with matrix degradation. Lab Invest. 1997;77:281-288.
88. Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environement. Wound Rep Reg. 1996;4:321-325.
89. Levy D, Lapierre F, Liang W, et al. Matrix metalloproteinase inhibitors: a structure activity study. J Med Chem. 1998;41:199-223.
90. Gomis-Ruth F, Maskos K, Betz M, et al. Mechanism of inhibition of human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 1997;389:77-81.
91. Dhanaraj V, Ye QZ, Johnson L, et al. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure. 1996;4:375-386.
92. Ye QZ, Hupe D, Johnson L. Catalytic domains of matrix metalloproteinases: a molecular biology approach to drug discovery. Curr Med Chem. 1996;3:407-418.
93. Beckett R, Whittaker M. Matrix metalloproteinase inhibitors. Exp Opin Ther Patents. 1998;8:259-282.
94. Levy D, Ezrin A. Matrix metalloproteinase inhibitor drugs. Emerg Drugs. 1997;2:205-230.
95. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115:3719-3727.
96. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19:6642-6650.
97. Rouis M, Adamy C, Duverger N, et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation. 1999;100:533-540.
98. Allaire E, Forough R, Clowes M, et al. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest. 1998;102:1413-1420.